Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02772705|
Recruitment Status : Unknown
Verified May 2016 by Li Yuhao, West China Hospital.
Recruitment status was: Recruiting
First Posted : May 13, 2016
Last Update Posted : May 13, 2016
|Condition or disease|
|Hyperthyroidism Tomography Emission-Computed Single-Photon|
Traditionally it is considered that only positron emission tomography(PET) has the ability to obtain standardized uptake value（SUV）while single-photo emission computed tomography(SPECT) does not have. Recently with the developing of technology, the ability of SPECT has been extended.
On the other hand, thyroid imaging by SPECT can only play an auxiliary role in hyperthyroidism diagnosis mainly since it is regarded as nonquantitative. So the investigators design this study to search the capacity and accuracy of SUV provided by SPECT and CT(CT is used for reconstruction algorithm) in diagnosing GD.
This is a multiple-center study containing nine groups in China that use GE Discovery NM/CT, an advanced equipment. Thus, the data can be more accurate and more available.
And this is a perspective clinical trial, taking about eight months. The investigators plan to evaluate at least 50 Grave's Disease(GD) patients and 50 normal humans as contrast in all.
Every GD patient must have been diagnosed and the results of thyroid function tests(such as TSH,FT3,FT4） must be available. If necessary, the patient's rate of iodine uptake should also be known before he/she being included in this study. As for normal people, the results of thyroid function tests should be within the range of normal value.
The data of each participant will be gathered and stored. And the data processing will be done with the help of GE staff, using the software Q.Metrix to get the value of SUVmean, SUVmax. Finally T test will be used in comparison of the differences.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||August 2016|
|Estimated Study Completion Date :||January 2017|
Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
- The thyroid imaging of GD patients and normal humans by SPECT/CT [ Time Frame: a single point in time, at subject enrollment ]For GD patients and normal healthy volunteers, we will get the data of thyroid fusion imaging by giving them a SPECT/CT check at subject enrollment.
- The SUV values of GD patients and normal humans provided by Q.Metrix [ Time Frame: a single point in time, at subject enrollment ]The data of thyroid fusion imaging will be processed by the software, Q.Metrix, which can get the accurate SUV by compensating for photon absorption within the body, removing scattered radiation and etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02772705
|Contact: Yahao Li, Bachelor||+86 firstname.lastname@example.org|
|Contact: Lin Li, Master||+86 email@example.com|
|Beijing Tongren Hospital||Recruiting|
|Beijing, Beijing, China, 100000|
|Contact: Mei Li, PH.D +86 18811612193 Lee_mei_bj@sina.com|
|Principal Investigator: Mei Li, PH.D|
|Guangzhou Panyu Central Hospital||Recruiting|
|Guangzhou, Guangdong, China, 510000|
|Contact: Yi Huang +86 13719231991 firstname.lastname@example.org|
|Principal Investigator: Yi Huang|
|Hebei General Hospital||Recruiting|
|Shijiazhuang, Hebei, China, 050000|
|Contact: Yanzhu Bian, PH.D +86 13073129364 email@example.com|
|Principal Investigator: Yanzhu Bian, PH.D|
|The First Affiliated Hospital of Zhengzhou University||Recruiting|
|Zhengzhou, Henan, China, 450000|
|Contact: Xingmin Han +86 13838178090 firstname.lastname@example.org|
|Principal Investigator: Xingmin Han|
|China, Inner Mongolia|
|The People's Hospital of Inner Mongolia Autonomous Region||Recruiting|
|Hohhot, Inner Mongolia, China, 010000|
|Contact: Juzhen Liu +86 13604718831 email@example.com|
|Principal Investigator: Juzhen Liu|
|Fourth Military Medical Universit||Recruiting|
|Xi'an, Shanxi, China, 710000|
|Contact: Guoquan Li, PH.D +86 15809252822 firstname.lastname@example.org|
|Principal Investigator: Guoquan Li, PH.D|
|West China Hospital||Recruiting|
|Chengdu, Sichuan, China, 610000|
|Contact: Lin Li, Master +86 13881833145 email@example.com|
|Principal Investigator: Yahao Li, Bachelor|
|Tianjin Medical University General Hospital||Recruiting|
|Tianjin, Tianjin, China, 300000|
|Contact: Feng Dong, Master +86 13502116364 Dongfeng1105@sina.com|
|Principal Investigator: Feng Dong, Master|
|Zhejiang Cancer Hospital||Recruiting|
|Hangzhou, Zhejiang, China, 310000|
|Contact: Linfa Li +86 13666670158 firstname.lastname@example.org|
|Principal Investigator: Linfa Li|
|Study Chair:||Lin Li, Master||West China Hospital of Sichuan University, Department of Nuclear Medicine|
|Study Director:||Xiaohong Ou, Ph.D||West China Hospital of Sichuan University, Department of Nuclear Medicine|
|Principal Investigator:||Yahao Li, Bachelor||West China Hospital of Sichuan University, Department of Nuclear Medicine|